1-Boc-4-(2-氨基苯基)哌嗪 | 170017-74-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 1-Boc-4-(2-氨基苯基)哌嗪
• 中文别名: 4-(2-氨基苯基)四氢吡嗪甲酸叔丁酯
• 英文名称: tert-butyl 4-(2-aminophenyl)piperazine-1-carboxylate
• 英文别名: 4-(2-aminophenyl)piperazine-1-carboxylic acid tert-butyl ester；1-[1,1-dimethylethoxycarbonyl]-4-(2-aminophenyl)piperazine；1-Boc-4-(2-Aminophenyl)piperazine
• CAS: 170017-74-0
• 化学式: C₁₅H₂₃N₃O₂
• 分子量: 277.367
• InChiKey: LNDQGWAWYKFYAO-UHFFFAOYSA-N

物化性质

• 沸点：
  416.3±40.0 °C(Predicted)
• 密度：
  1.145±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  58.8
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险品标志：
  Xi
• 海关编码：
  2933599090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H312,H315,H319,H332,H335
• 储存条件：
  室温和干燥环境下使用。

SDS

Name:	tert-Butyl 4-(2-aminophenyl)tetrahydro-1(2h)-pyrazinecarboxylate Material Safety Data Sheet
Synonym:	None Known
CAS:	170017-74-0

Section 1 - Chemical Product MSDS Name:tert-Butyl 4-(2-aminophenyl)tetrahydro-1(2h)-pyrazinecarboxylate Material Safety Data Sheet
Synonym:None Known

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
170017-74-0	tert-Butyl 4-(2-aminophenyl)tetrahydro	97+%	unlisted

Hazard Symbols: XN
Risk Phrases: 20/21/22

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Harmful by inhalation, in contact with skin and if swallowed.The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation. Harmful if absorbed through the skin.
Ingestion:
Harmful if swallowed. May cause irritation of the digestive tract.
The toxicological properties of this substance have not been fully investigated.
Inhalation:
Harmful if inhaled. May cause respiratory tract irritation. The toxicological properties of this substance have not been fully investigated.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: In case of contact, immediately flush eyes with plenty of water for at least 15 minutes. Get medical aid.
Skin:
In case of contact, flush skin with plenty of water. Remove contaminated clothing and shoes. Get medical aid if irritation develops and persists. Wash clothing before reuse.
Ingestion:
If swallowed, do not induce vomiting unless directed to do so by medical personnel. Never give anything by mouth to an unconscious person. Get medical aid.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions.
Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Use with adequate ventilation.
Minimize dust generation and accumulation. Avoid breathing dust, vapor, mist, or gas. Avoid contact with eyes, skin, and clothing.
Keep container tightly closed. Avoid ingestion and inhalation.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 170017-74-0: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: Brown
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 119 - 124 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C15H23N3O2
Molecular Weight: 277.37

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials, dust generation.
Incompatibilities with Other Materials:
Strong oxidizing agents, acid chlorides, strong acids.
Hazardous Decomposition Products:
Carbon monoxide, oxides of nitrogen, carbon dioxide.
Hazardous Polymerization: Will not occur.

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 170017-74-0 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
tert-Butyl 4-(2-aminophenyl)tetrahydro-1(2h)-pyrazinecarboxylate - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2811
Packing Group: III
IMO
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2811
Packing Group: III
RID/ADR
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2811
Packing group: III

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XN
Risk Phrases:
R 20/21/22 Harmful by inhalation, in contact with
skin and if swallowed.
Safety Phrases:
S 22 Do not breathe dust.
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
WGK (Water Danger/Protection)
CAS# 170017-74-0: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 170017-74-0 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 170017-74-0 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-Boc-4-(2-氨基苯基)哌嗪 在 tris-(dibenzylideneacetone)dipalladium(0) 、 硫酸 、 R-(+)-1,1'-联萘-2,2'-双二苯膦 、 sodium t-butanolate 、 sodium nitrite 作用下， 以 水 、 甲苯 为溶剂， 反应 27.0h， 生成 4-[2-(2,4-二甲基苯基磺酰基)苯基]哌嗪-1-羧酸叔丁酯
  参考文献：
  名称：

  NEW VORTIOXETINE INTERMEDIATE AND SYNTHESIS PROCESS THEREOF

  摘要：

  本发明提供了一种新的中间体II及其合成方法。该方法包括：(a)首先将化合物I作为原料重氮化，然后卤代化以获得中间体II；以及(b)将中间体II与化合物III反应以获得化合物IV，直接水解所得的化合物IV而不进行分离，从而获得化合物V代表的Vortioxetine。中间体II可用于合成Vortioxetine。

  公开号：

  US20170088530A1
• 作为产物：
  描述：

  硝基氯苯 在 5%-palladium/activated carbon 、 氢气 、 potassium carbonate 作用下， 以 乙醇 、 二甲基亚砜 为溶剂， 反应 62.5h， 生成 1-Boc-4-(2-氨基苯基)哌嗪
  参考文献：
  名称：

  アセチルコリン小胞トランスポーターの検出に適した化合物

  摘要：

  提供一种适用于检测乙酰胆碱囊泡转运体的化合物，可用作PET法的标记化合物。该化合物由式（I）表示。（在式（I）中，R1表示CH3、F、（CH2）n-F、NH-(CH2)n-F、O-(CH2)n-F或S-(CH2)n-F（其中n表示1~3的整数）。）【选择图】无

  公开号：

  JP2018119009A

文献信息

• PYRROLE mTORC INHIBITORS AND USES THEREOF
  申请人：Navitor Pharmaceuticals, Inc.

  公开号：US20190389843A1

  公开（公告）日：2019-12-26

  The present invention provides compounds, compositions thereof, and methods of using the same.

  本发明提供了化合物、其组合物以及使用这些化合物的方法。
• [EN] PYRROLE mTORC INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS PYRROLES DE MTORC ET LEURS UTILISATIONS
  申请人：NAVITOR PHARM INC

  公开号：WO2018089493A1

  公开（公告）日：2018-05-17

  The present invention provides compounds, compositions thereof, and methods of using the same.

  本发明提供了化合物、其组合物以及使用这些化合物的方法。
• Anti-aids piperazines
  申请人：The Upjohn Company

  公开号：US05489593A1

  公开（公告）日：1996-02-06

  The present invention includes diaromatic substituted heterocyclic compounds (III) ##STR1## which are useful in treating individuals infected with the HIV virus. The invention includes certain previously generically disclosed anti-AIDS piperazinyl compounds (V) and a method of treating HIV infected individuals with the indoles of formula (V) and the anti-AIDS amines (X).

  本发明包括二芳基取代的杂环化合物（III）##STR1##，其可用于治疗感染HIV病毒的个体。本发明还包括某些先前一般性披露的抗艾滋病哌嗪基化合物（V）以及一种使用吲哚类化合物（V）和抗艾滋病胺类（X）治疗HIV感染个体的方法。
• Substituted piperazines and methods of use
  申请人：——

  公开号：US20030220324A1

  公开（公告）日：2003-11-27

  Selected substituted piperazine compounds are effective for prophylaxis and treatment of diseases, such as obesity and the like. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving activation of the melanocortin receptor. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

  选择的替代哌嗪化合物对于预防和治疗疾病，如肥胖等，具有有效性。该发明涵盖了新型化合物、类似物、前药和其药用盐，以及用于预防和治疗涉及黑素皮质素受体激活的疾病和其他疾病或病症的药物组合物和方法。该发明还涉及制备这类化合物的方法，以及在这些过程中有用的中间体。
• Synthesis and Structure-Activity Relationships of New 2-Phenoxybenzamides with Antiplasmodial Activity
  作者：Theresa Hermann、Patrick Hochegger、Johanna Dolensky、Werner Seebacher、Eva-Maria Pferschy-Wenzig、Robert Saf、Marcel Kaiser、Pascal Mäser、Robert Weis

  DOI：10.3390/ph14111109

  日期：——

  promising multi-stage activity against different strains of P. falciparum. It was successfully synthesized via a retrosynthetic approach. Subsequently, twenty-one new derivatives were prepared and tested for their in vitro activity against blood stages of the NF54 strain of P. falciparum. Several insights into structure-activity relationships were revealed. The antiplasmodial activity and cytotoxicity of

  来自疟疾风险药物盒项目的 2-苯氧基苯甲酰胺1已显示出针对不同恶性疟原虫菌株的多阶段活性。它是通过逆合成方法成功合成的。随后，制备了 21 种新衍生物并测试了它们对恶性疟原虫NF54 菌株血液阶段的体外活性. 揭示了对结构-活性关系的一些见解。化合物的抗疟原虫活性和细胞毒性在很大程度上取决于苯胺基部分结构的取代模式以及取代基的大小。二芳基醚部分结构对活性有进一步影响。此外，计算了几个物理化学和药代动力学参数（log P、log D 7 . 4和配体效率）或通过实验确定（被动渗透性和 CYP3A4 抑制）。的叔丁基-4- 4- [2-（4-氟苯氧基）-3-（三氟甲基）苯甲酰氨基]苯基}哌嗪-1-羧酸叔丁酯具有针对高抗疟原虫活性的恶性疟原虫NF54（Pf的NF54 IC 50= 0.2690 µM) 和非常低的细胞毒性（L-6 细胞 IC 50 = 124.0 µM），从而获得了 460 的